Connect with us

News

Sotorasib (AMG 510) Shows Promising Results in Some Patients With Solid Tumors, Suggests a Study With City of Hope as a Co-Lead Author

gbafNews28

A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a new study led by City of Hope and other renowned comprehensive cancer centers.

The multisite clinical trial included 129 metastatic cancer patients who had received an average of three prior therapies. These patients all had the mutated KRAS G12C gene, which increases the chances that an individual will be diagnosed with an aggressive cancer resistant to treatment.

We have finally shown that RAS targeting and inhibition is feasible. We hope that this will be the first step amongst many to effectively treat RASmutant cancers, one of the most common drivers of cancer, said Marwan Fakih, M.D., medical oncologist at City of Hope and co-lead author of the New England Journal of Medicine study that published today.

The KRAS gene, discovered nearly 40 years ago, is known as an oncogene. When mutated, KRAS could activate a pathway that turns normal cells cancerous. This gene belongs to the RAS gene family, which is responsible for more than 30% of all human cancers, according to the National Cancer Institute.

KRAS mutations have been linked with worse treatment outcomes in a variety of cancers, including lung and colorectal cancers, Fakih added. This proof-of-concept study has, in some cases, demonstrated a median progression-free survival that is two times longer than what we encounter in patients today.

The purpose of the clinical trial was to test the safety of various doses of sotorasib (180mg, 360mg, 720mg and 960mg), which were taken orally once a day. Patients had refractory metastatic non-small cell lung cancer (59 participants), colorectal cancer (42 participants) or other tumor types (28 participants). Their average age was 62, and the median follow-up was 12 months.

Sotorasib is a small molecule that inhibits KRAS G12C by plugging up a specific pocket (P2), inhibiting the ability of this mutated KRAS protein from driving tumor growth and spread. Current studies show that the drug, while able to target many cancers, appears to be most potent in non-small cell lung cancer, where KRAS G12C mutations exist in about 13% of patients.

The KRAS G12C inhibitor sotorasib produced lasting clinical benefits with mostly minor side effects that affected the gastrointestinal tract and included diarrhea (30%), fatigue (23%) and nausea (21%). Although trial patients had stubborn cancers resistant to standard-of-care treatments, those with non-small cell lung cancer had a 32% response rate with the majority (88%) achieving disease control for at least a few months. Their median progression-free survival was 6.3 months. This is a great improvement considering that later lines of treatment in non-small cell lung cancer are typically associated with response rates of only 9-18% and a median progression-free survival of approximately three months.

The other group that saw notable benefit were patients with refractory metastatic colorectal cancer a response rate of about 7%, disease control rate of 74% and major tumor shrinkage in 7% of the group, Fakih said. The median progression-free survival was four months. In comparable lines of treatment, response rates are rarely experienced, and the median progression-free survival is approximately two months.

The benefits of sotorasib appear to be quite durable with at least half of metastatic colorectal cancer patients still experiencing disease control four months after the start of treatment, Fakih said. When you consider the poor prognosis for the metastatic setting and the lack of effective treatments for this population, controlling tumor progression for a few additional months with an oral therapy is a significant and meaningful outcome.

Treatment was discontinued in 107 patients (83%), mostly because of disease progression. Fifty-four patients had died, a reasonable outcome given the prognosis and late stage of the disease.

Fakih, director of the Gastrointestinal Cancer Program at City of Hope, is involved in two sotorasib (AMG 510) clinical trials with a total of six treatment arms to evaluate use of sotorasib as a monotherapy or combination treatment in patients with non-small cell lung cancer, colorectal cancer and other solid tumors.

The inconsistency in tumor response between non-small cell lung cancer and colorectal cancer suggests that KRAS G12C inhibition is not sufficient for colorectal cancer and that additional cancer-causing pathways must be switched off, Fakih said. Combining sotorasib with other therapies that block the epidermal growth factor receptor (EGFR), a protein whose overexpression has been linked to many cancers, is a promising path forward that is under investigation, he added.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

The study was supported by Amgen Inc., Cancer Prevention & Research Institute of Texas (RP150535, P30 CA016672), Fox Chase Cancer Centers National Institutes of Health grant (P30 CA006927), Memorial Sloan Kettering Cancer Centers NIH grant (P30 CA008748), NIH/NCI (1R01CA23074501, 1R01CA23026701A1), The Pew Charitable Trusts and the Damon Runyon Cancer Research Foundation.

Zen Vuong

626-409-9367

[email protected]

News

Boston Omaha Announces Closing of Yellowstone Acquisition Company $125 Million Initial Public Offering

gbafNews28

Boston Omaha Corporation (NASDAQ:BOMN) (Boston Omaha) announced today that Yellowstone Acquisition Company (Yellowstone) closed its initial public offering (the IPO) of 12,500,000 units at a price of $10.00 per unit, resulting in gross proceeds of $125,000,000. The units began trading on the NASDAQ Stock Market, LLC (NASDAQ) under the ticker symbol YSACU on October 22, 2020. BOC Yellowstone LLC, a subsidiary of Boston Omaha, served as the sponsor (the Sponsor) for Yellowstones IPO.

Each unit issued in the IPO consists of one share of Yellowstones Class A common stock and one-half of one warrant, each whole warrant entitling the holder thereof to purchase one share of Class A common stock at an exercise price of $11.50 per share. After the securities comprising the units begin separate trading, the shares of Class A common stock and warrants are expected to be listed on NASDAQ under the symbols YSAC and YSACW, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

The Sponsor has purchased an aggregate of 7,500,000 warrants (which can increase to 7,875,000 warrants if the over-allotment option is exercised in full) at a price of $1.00 per whole warrant ($7,500,000 in the aggregate, or $7,875,000 if the over-allotment option is exercised in full) in a private placement that closed simultaneously with the closing of the IPO (the “private placement warrants). Each whole private placement warrant is exercisable to purchase one whole share of Yellowstone’s Class A common stock at $11.50 per share. In addition, the Sponsor acquired 3,593,750 shares of Yellowstone’s Class B common stock (up to 468,750 shares of which are subject to forfeiture depending on the extent to which the underwriters over-allotment option is exercised) for a purchase price of $25,000. The shares of Class B common stock will automatically convert into shares of Class A common stock at the time, if any, when Yellowstone completes an initial business combination, on a one-for-one basis, subject to certain adjustments. In the event a business combination is not consummated within 15 months following the IPO, then $127,500,000 of the proceeds raised in the IPO and through the sale of the private placement warrants will be paid to redeem the shares of Class A common stock sold to the public.

  • No officer or director of Boston Omaha shall receive any equity issued to the Sponsor.
  • Yellowstone has not selected any potential business combination target.

The purpose of the IPO is to pursue a business combination in an industry other than the three industries in which Boston Omaha currently owns and operates businesses: outdoor advertising, surety insurance and broadband services businesses. For further information regarding the terms of the IPO and the rights and obligations of the Sponsor, please refer to the Yellowstone Prospectus on file with the SEC at www.sec.gov.

Boston Omaha elected to proceed with a SPAC public offering for the following reasons:

  • Boston Omaha intends to use its existing capital for the three business lines in which it currently operates: outdoor advertising, surety insurance and fiber-to-the-home broadband services as well as investing in other future potential acquisitions and making other investments. By teaming with other public investors in the IPO, Yellowstone has the ability to pursue business combinations with larger companies than Boston Omaha could pursue currently on a stand-alone basis.
  • There are many owner-operated businesses interested in minority owners for growth capital. Boston Omaha has invested in a number of these types of businesses. However, Boston Omaha’s ability to acquire a significant equity stake in a larger business through a business combination is limited by the Investment Company Act of 1940 (as amended), which requires a company which holds more than 40% of its assets in minority investments in other businesses to register under the Investment Company Act. This requirement prevents Boston Omaha on a stand-alone basis from consummating larger deals in which it would own a minority interest in a business, thus currently preventing or otherwise significantly limiting its ability to engage in larger business combinations.
  • Acquiring a large percentage of equity in certain businesses, such as regulated financial institutions, would require Boston Omaha to comply with very burdensome and expensive regulations which would both limit its overall business operations due to capital and other financial testing covenants and adversely impact its ability to acquire other businesses which would not otherwise be subject to these regulations.

Wells Fargo Securities served as the sole book runner for the IPO. Yellowstone has granted the underwriters a 45-day option to purchase up to an additional 1,875,000 units at the initial public offering price to cover over-allotments, if any.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from Wells Fargo Securities, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email a request to [email protected]. A registration statement relating to the securities offered by Yellowstone was filed with the Securities and Exchange Commission (SEC) and became effective on October 21, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

ABOUT YELLOWSTONE

Yellowstone, led by Adam Peterson and Alex Rozek, is a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses with an intention to initially focus on potential combinations in the homebuilding, manufacturing serving the homebuilding market, financial services and commercial real estate industries. To contact Yellowstone, please visit www.yellowstoneac.com or email Yellowstone at [email protected].

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Boston Omaha or Yellowstone, including those set forth in the Risk Factors section of Yellowstones registration statement and prospectus for the offering filed with the SEC. Copies are available on the SECs website at www.sec.gov. Boston Omaha and Yellowstone undertake no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:

Catherine Vaughan

[email protected]

Continue Reading

News

Community Health Systems Completes Divestiture of Two Texas Hospitals

gbafNews28

Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company have completed the sale of two Texas hospitals “ 231-bed Abilene Regional Medical Center in Abilene and 188-bed Brownwood Regional Medical Center in Brownwood and their associated assets “ to subsidiaries of Hendrick Health System. The effective date of the transactions is October 27, 2020. With the divestitures completed, Community Health Systems affiliates continue to operate seven hospitals in Texas.

As part of the transaction, Hendrick has secured assignment of the long-term lease and operations of Brownwood Regional Medical Center from the Brownwood County Hospital Authority.

The hospitals in this transaction are among the planned divestitures discussed on the Companys second quarter 2020 earnings call.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the largest publicly traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. The Company, through its subsidiaries, owns, leases or operates 89 affiliated hospitals in 16 states with an aggregate of approximately 15,000 licensed beds. The Companys headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol CYH. More information about the Company can be found on its website at www.chs.net.

Forward-Looking Statements

Statements contained in this news release regarding potential transactions, operating results, and other events are forward-looking statements that involve risk and uncertainties. Actual future events or results may differ materially from these statements. Readers are referred to the documents filed by Community Health Systems, Inc. with the Securities and Exchange Commission, including the Companys annual report on Form 10-K, current reports on Form 8-K and quarterly reports on Form 10-Q. These filings identify important risk factors and other uncertainties that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kevin Hammons, 615-465-7000

Executive Vice President and Chief Financial Officer

or

Ross W. Comeaux, 615-465-7012

Vice President – Investor Relations

Media Contact:

Tomi Galin, 615-628-6607

Senior Vice President, Corporate

Communications, Marketing and Public Affairs

Continue Reading

News

Commercial Telematics Market Growth will Accelerate at a CAGR of 10% during 2020-2024 | Technavio

gbafNews28

Technavio has been monitoring the commercial telematics market, operating under the information technology industry. The latest report on the commercial telematics market, 2020-2024 estimates it to register an incremental growth of USD 23.15 bn, at a CAGR of almost 10% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.

Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download Latest Free Sample Report on COVID-19 Analysis

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Competitors have to focus on differentiating their product offerings with unique value propositions to strengthen their foothold in the market. Market vendors also have to leverage on the existing growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments. Bridgestone Corp., Continental AG, General Motors Co., Geotab Inc., Omnitracs LLC, Trimble Inc., Verizon Communications Inc., Visteon Corp., Volkswagen Group, and Volvo Group are among some of the major market participants.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The increasing adoption of driver assistance systems has been instrumental in driving the growth of the market. Vendors are focusing on the development of usage-based insurance (UBI) in connected cars and smart apps, which will also contribute to the growth of the commercial telematics market. However, the complexity of telematics software and hardware design might hamper market growth.

Technavio’s custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations. Download a Free Sample Report on COVID-19 Impacts

Commercial Telematics Market 2020-2024: Segmentation

Commercial Telematics Market is segmented as below:

  • Product
    • Solutions
    • Services
  • Platform
    • Embedded Systems
    • Tethered Systems
    • Smartphone Integration Systems
  • Geographic Landscape
    • APAC
    • Europe
    • MEA

Commercial Telematics Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The commercial telematics market report covers the following areas:

  • Commercial Telematics Market Size
  • Commercial Telematics Market Trends
  • Commercial Telematics Market Industry Analysis

This study identifies the growth of embedded telematics solutions as one of the primary trends anticipated to boost the Commercial Telematics Market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Commercial Telematics Market 2020-2024: Key Highlights

  • CAGR of the market during the forecast period 2020-2024
  • Detailed information on factors that will assist commercial telematics market growth during the next five years
  • Estimation of the commercial telematics market size and its contribution to the parent market
  • Predictions on upcoming trends and changes in consumer behavior
  • The growth of the commercial telematics market
  • Analysis of the markets competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of commercial telematics market vendors

Table of Contents:

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 – 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product placement
  • Solutions – Market size and forecast 2019-2024
  • Services – Market size and forecast 2019-2024
  • Market opportunity by Product

Market Segmentation by Platform

  • Market segments
  • Comparison by Platform placement
  • Embedded systems – Market size and forecast 2019-2024
  • Tethered systems – Market size and forecast 2019-2024
  • Smartphone integration systems – Market size and forecast 2019-2024
  • Market opportunity by Platform

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2019-2024
  • Europe – Market size and forecast 2019-2024
  • APAC – Market size and forecast 2019-2024
  • South America – Market size and forecast 2019-2024
  • MEA – Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver – Demand led growth
  • Volume driver – Supply led growth
  • Volume driver – External factors
  • Volume driver – Demand shift in adjacent markets
  • Price driver – Inflation
  • Price driver – Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption
  • Vendor Analysis

Vendors covered

  • Market positioning of vendors
  • Bridgestone Corp.
  • Continental AG
  • General Motors Co.
  • Geotab Inc.
  • Omnitracs LLC
  • Trimble Inc.
  • Verizon Communications Inc.
  • Visteon Corp.
  • Volkswagen Group
  • Volvo Group

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News35 mins ago

Boston Omaha Announces Closing of Yellowstone Acquisition Company $125 Million Initial Public Offering

Boston Omaha Corporation (NASDAQ:BOMN) (Boston Omaha) announced today that Yellowstone Acquisition Company (Yellowstone) closed its initial public offering (the IPO)...

gbafNews28 gbafNews28
News46 mins ago

Community Health Systems Completes Divestiture of Two Texas Hospitals

Community Health Systems, Inc. (NYSE: CYH) announced today that subsidiaries of the Company have completed the sale of two Texas...

gbafNews28 gbafNews28
News48 mins ago

Energy Transfer Announces Quarterly Cash Distribution and Earnings Release and Earnings Call Dates

Energy Transfer LP (NYSE: ET) today announced a quarterly cash distribution of $0.1525 per ET common unit ($0.61 on an...

gbafNews28 gbafNews28
News48 mins ago

Commercial Telematics Market Growth will Accelerate at a CAGR of 10% during 2020-2024 | Technavio

Technavio has been monitoring the commercial telematics market, operating under the information technology industry. The latest report on the commercial...

gbafNews28 gbafNews28
News50 mins ago

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allergan plc and Encourages Investors with Losses of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors...

gbafNews28 gbafNews28
News54 mins ago

LG Chem Responds to Delay in ITC Ruling on Trade Secret Case

The US International Trade Commission announced Monday it would extend until December 10 its investigation of the trade secret dispute...

gbafNews28 gbafNews28
News58 mins ago

Cable One Announces Pricing of Upsized Private Offering of $650 Million of Senior Notes

Cable One, Inc. (NYSE: CABO) (Cable One or the Company) today announced the pricing of the previously announced private offering...

gbafNews28 gbafNews28
News60 mins ago

Securian Financial Is First U.S. Direct Life Insurer to Complete a Mortality Insurance-Linked Security Transaction

Securian Financial affiliate, Minnesota Life Insurance Company, has successfully completed a $100 million insurance-linked security (ILS) transaction, becoming the first...

gbafNews28 gbafNews28
News2 hours ago

AIG Announces Third Quarter 2020 Catastrophe Loss Estimates, including COVID-19 Catastrophe-Related Loss Estimates; and Results of the Life & Retirement and Legacy Annual Actuarial Assumption Update

American International Group, Inc. (NYSE: AIG) today announced its General Insurance catastrophe losses, including COVID-19 catastrophe-related losses, for the quarter...

gbafNews28 gbafNews28
News2 hours ago

AIG to Pursue Separation of Life & Retirement Business

American International Group, Inc. (NYSE: AIG) today announced its intention to separate its Life & Retirement business from AIG. The...